Form 8-K

8-K — Imunon, Inc.

Accession: 0001493152-26-013816

Filed: 2026-03-31

Period: 2026-03-31

CIK: 0000749647

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0000749647

2026-03-31

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

DC 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): March 31, 2026

Imunon,

Inc.

(Exact

name of registrant as specified in its Charter)

Delaware

001-15911

52-1256615

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

997

Lenox Drive, Suite 100, Lawrenceville, NJ

08648-2311

(Address

of principal executive offices)

(Zip

Code)

(609)

896-9100

(Registrant’s

telephone number, including area code)

N/A

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act

Title

of each class

Trading

symbol(s)

Name

of each exchange on which registered

Common

stock, par value $0.01 per share

IMNN

Nasdaq

Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933

(§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

2.02 Results of Operations and Financial Condition.

March 31, 2026, Imunon, Inc. issued a press release reporting its financial results for the year ended December 31, 2025. A copy of the

press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

March 24, 2026, Imunon, Inc. announced it would hold a conference call on March 31, 2026 to discuss its financial results for the year

ended December 31, 2025 and provide a business update. The conference call will also be broadcast live on the internet at https://edge.media-server.com/mmc/p/zzmqzars/.

The

information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes

of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections

11 and 12(a)(2) of the Securities Act of 1933, as amended. Such information shall not be incorporated by reference into any filing with

the Securities and Exchange Commission made by Imunon, Inc., whether made before or after the date hereof, regardless of any general

incorporation language in such filing.

The

press release contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ

materially from those expressed or implied by such statements. Please refer to the cautionary note in the press release regarding these

forward-looking statements.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

99.1

Press Release dated March 31, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

IMUNON

INC.

Dated:

March 31, 2026

By:

/s/

Jeffrey Church

Jeffrey

Church

Chief

Financial Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

IMUNON

Reports 2025 Financial Results and Provides Business Update

Highlighting Significant Progress with Pivotal Phase 3 Study

IMNN-001

is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly

diagnosed with advanced ovarian cancer

Final

Phase 2 clinical data show continued median overall survival improvement with IMNN-001

Enrollment

in the OVATION 3 Study, IMUNON’s Phase 3 pivotal trial for IMNN-001, remains ahead of plan supported by continued strong interest

from principal investigators and the medical community

Company

to hold conference call today at 11:00 a.m. EDT

LAWRENCEVILLE,

N.J., March 31, 2026 (GLOBE NEWSWIRE) – IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in late-stage development

with its DNA-mediated immunotherapy, today reported financial results for the year ended December 31, 2025, and highlighted recent business

updates including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian

cancer.

“IMUNON

continues to make significant progress in advancing IMNN-001, a potential breakthrough for women with newly diagnosed advanced ovarian

cancer,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “A final data assessment of

the Phase 2 OVATION 2 Study indicates that treatment with IMNN-001 was associated with an overall survival benefit of more than a year

in patients treated with IMNN-001 plus chemotherapy and more than two years in women also receiving PARP inhibitors as part of maintenance

therapy.”

“Unprecedented

survival data results from the Phase 2 OVATION 2 Study, coupled with compelling interim results

from our MRD study and a clear regulatory path in Phase 3, position IMNN-001 with the potential to deliver transformative impact on ovarian

cancer treatment. These new results showing continued improvements in overall survival are especially exciting given that there

have been virtually no advances in frontline standard of care for women newly diagnosed with ovarian cancer in the last 35 years,”

Dr. Lindborg continued.

RECENT

DEVELOPMENTS

IMNN-001

Immunotherapy

Final

Phase 2 OVATION 2 Study Data Show Continued Overall Survival Improvement with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian

Cancer – On March 25, 2026, the Company announced final data from the completed Phase 2 OVATION 2 clinical trial evaluating

IMNN-001 in combination with standard of care (SoC) neoadjuvant and adjuvant chemotherapy (N/ACT) in 112 women with newly diagnosed advanced

ovarian cancer. IMUNON previously reported a median 11.1 month increase in overall survival (40.5 vs. 29.4 months) in the IMNN-001 treatment

arm compared to SoC chemotherapy alone. Following the most recent data assessment, the Company reported a median 14.7 month increase

in overall survival (45.1 vs. 30.4 months) in women in the IMNN-001 treatment arm compared to SoC alone, demonstrating continuous improvement

in overall survival (3.6 delta). In addition, the new IMNN-001 data showed that women treated with IMNN-001 and SoC chemotherapy plus

poly ADP-ribose polymerase (PARP) inhibitors as part of maintenance therapy achieved a median increase in overall survival of 24.2 months

(65.6 vs. 41.4 months) compared to SoC chemotherapy alone.

Importantly,

with these new efficacy results, IMNN-001 continued to show a highly favorable safety and tolerability profile, further reinforcing the

potential of this IL-12 immunotherapy to represent a landmark advance in treatment of this disease.

R&D

Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer – On November

10, 2025, the Company hosted an R&D Day, providing updates on new IMNN-001 data and discussing progress with the Phase 3 OVATION

3 Study and IMNN-001’s potential role in transforming the treatment landscape for women with advanced ovarian cancer. Highlights

from the R&D Day are summarized below.

Data

from the Phase 2 OVATION 2 clinical trial:

○

Broad

impact observed with IMNN-001 treatment on important cancer-fighting cytokines, effectively turning the tumor microenvironment from

“cold” to “hot” by activating both innate and adaptive immune systems, renewing the elusive promise of an

immunotherapy for ovarian cancer.

○

Data

reinforcing the highly favorable benefit-risk and safety profile of IMMN 001.

○

The

remarkable median 13-month overall survival (OS) benefit observed with IMNN-001 plus standard of care (SoC) chemotherapy, an increase

that is considered clinically meaningful compared to SoC alone.

Safety,

tolerability and translational insights from the Phase 2 minimal residual disease (MRD) study of IMNN-001:

○

Rationale

for the trial and the importance of frontline therapy as the best opportunity to achieve a cure for ovarian cancer.

○

New

translational data that show IMNN-001 preferentially being taken up by macrophages within the peritoneal fluid and tumor tissue,

which then induces a robust response and tumor microenvironment remodeling.

○

New

data supporting the highly favorable benefit-risk and tolerability profile of IMNN-001.

○

The

positive tolerability profile of IMNN-001, including in combination with SoC chemotherapy plus bevacizumab, and in the maintenance

setting.

Phase

2 and ongoing Phase 3 trial designs, and the strength of evidence for IMNN-001 from a statistical perspective:

○

The

well-precedented nature of the Phase 3 trial design, which leverages an innovative, adaptive, event-driven approach aligned with

prior successful oncology trials that resulted in full approval by the U.S. Food and Drug Administration (FDA) based on an interim

analysis of overall survival.

○

This

foundation, supported by conservative power assumptions drawn from Phase 2 clinical data, strong simulation modeling and robust statistical

properties, underpins the Phase 3 trial’s high probability for success.

New

data further demonstrating IMNN-001 shifted the balance in favor of immune stimulation, remodeling the tumor microenvironment in favor

of anti-tumor responses, which is established to be associated with better prognosis.

The

presentations from the R&D Day are available on the “Scientific Presentations” page of the IMUNON website at https://investors.imunon.com/scientific-presentations.

Translational

Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting – On November 7, 2025, the Company presented translational

data from the Phase 2 OVATION 2 clinical trial of IMNN-001

at the Society for Immunotherapy of Cancer (SITC)

40th Annual Meeting, held on November 5-9, 2025, in National Harbor,

Maryland.

○

New

data from recently analyzed OVATION 2 Study patient samples demonstrated that IMNN-001 creates a “hot” anti-tumor microenvironment

in epithelial ovarian cancer by (i) increasing the recruitment of anti-tumor CD8+, myeloid dendritic cells and M1 macrophages in

patient tumors; and (ii) decreasing immunosuppressive markers (IDO, T regulatory [Treg] cells, exhausted CD8, M2 macrophages). These

results, including induction of favorable ratios of CD8+/Tregs and CD8+/CD4+ cells, which are both associated with improved patient

outcomes, are consistent with the results of the previous OVATION 1 study and with the efficacy seen in the clinic in the OVATION

2 study. This biomarker research confirms local immune activation at the tumor site by IMNN-001.

The

SITC poster presentation is available on the “Scientific Presentations” page of the IMUNON website at https://investors.imunon.com/scientific-presentations.

Phase

3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at the ESMO Congress and the IGCS 2025 Annual Global Meeting – On

October 14, 2025, the Company announced that a trials-in-progress abstract on the ongoing Phase 3 OVATION 3 clinical trial of IMNN-001

were being presented at the European Society for Medical Oncology (ESMO) Congress 2025, held on October 17-21, 2025, in Berlin, Germany

with an encore presentation following at the 2025 Annual Global Meeting of the International Gynecologic Cancer Society (IGCS), held

on November 5-7, 2025, in Cape Town, South Africa. The poster presentations are available on the “Scientific Presentations”

page of the IMUNON website at https://investors.imunon.com/scientific-presentations.

PlaCCine®

DNA Vaccine Technology

PlaCCine®

DNA Technology Proof-of-Concept Data Presented in Platform Presentations at Leading Vaccine Conferences – On October 17, 2025,

the Company announced oral presentations highlighting IMNN-101, its proof-of-concept DNA plasmid vaccine based on the Company’s

proprietary PlaCCine® technology platform, including proof-of-concept clinical trial results at the following vaccine

conferences:

●

5th

Edition of International Vaccines Congress (IVC) Keynote Oral Presentation: A promising novel approach to DNA vaccines,

presented on October 23, 2025

●

10th

International Conference on Vaccine Research and Development Oral Presentation: Development of a PlaCCine DNA Technology for

Safe, Effective and Durable Vaccines, presented on November 6, 2025

These

presentations described the unique design and composition of the PlaCCine technology and its differentiating features including a longer

duration of antigen expression, safety, and user compliance, and storage stability at workable temperatures (up to one year at 4°C

and one month at 37°C) in comparison to mRNA vaccines and other DNA vaccines requiring viruses or devices for delivery. The immunogenicity

of the PlaCCine technology was demonstrated against various pathogens in multiple species and animal models. These presentations also

demonstrated safety and immunogenicity of a PlaCCine based vaccine (IMNN-101) targeting a SARS-CoV-2 spike variant in healthy human participants

following intramuscular administration. Durable neutralizing antibody (Nab) responses from baseline at six months demonstrating vaccine

immunogenicity following a single dose in previously vaccinated or infected individuals with the SARS-CoV-2 underscore the significance

of the PlaCCine approach and support continued development in both naive populations using a prime and boost vaccination to determine

optimal benefits and in other infectious diseases.

IMNN-101

has been shown to be safe and well tolerated, with no serious adverse effects reported. To advance the development and commercialization

of the PlaCCine platform in the prophylactic vaccine competitive landscape, IMUNON will require a strategic partnership(s) with a pharmaceutical

or biotechnology company.

CORPORATE

DEVELOPMENTS

IMUNON

Sharpens Focus on its Promising Pivotal Phase 3 Ovarian Cancer Study – On February 5, 2026, the Company announced a strategic

reorganization, the goal of which was to reduce operating expenses while supporting the Company’s focused strategy to rapidly advance

the pivotal Phase 3 OVATION 3 clinical trial.

$7.0

Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules – On December 30, 2025, the Company announced that

it entered into a securities purchase agreement for the purchase and sale of 1,939,114 shares of common stock (or pre-funded warrants

in-lieu thereof), together with warrants to purchase up to an aggregate of 1,939,114 shares of common stock. Each share of common stock

(or pre-funded warrant in-lieu thereof) was sold together with one warrant to purchase one share of common stock at a combined purchase

price of $3.61 (or $3.6099 per pre-funded warrant and warrant). The warrants have an exercise price of $3.482 per share, and became exercisable

immediately upon issuance, and will expire five years from the date of issuance. The offering closed on December 31, 2025.

FINANCIAL

RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025

Cash

Management Continues to Focus on the Phase 3 OVATION 3 Study –

IMUNON

reported a net loss for 2025 of $14.5 million, or $6.83 per share, compared with a net loss of $18.6 million, or $16.94 per share, for

2024. Operating expenses were $14.7 million for 2025; a 23% decrease compared to 2024.

Research

and development (R&D) expenses were $7.8 million for 2025; a 33% decrease compared to 2024. The decrease was due primarily to lower

costs associated with the OVATION 2 Study, the Phase 1 proof-of-concept PlaCCine DNA vaccine trial, and development of the PlaCCine DNA

vaccine technology platform, partially offset by start-up costs associated with the pivotal Phase 3 OVATION 3 Study.

General

and administrative (G&A) expenses were $6.9 million for 2025, a decrease of 8% compared to 2024. This decrease was primarily attributable

to headcount reductions and lower employee-related expenses.

Net

cash used for operating activities was $13.9 million for full year 2025 compared with $18.9 million for full year 2024. Cash provided

by financing activities of $17.1 million for 2025 resulted from two offerings in May 2025 and December 2025 ($13.6 million) and sales

under the Company’s at-the-market equity facility ($3.5 million).

of December 31, 2025, cash and cash equivalents were $8.8

million.

Conference

Call and Webcast

The

Company will be hosting a conference call to review 2025 financial results and provide a business update today, March 31, 2026, at 11:00

a.m. EDT. To participate in the call, please dial 800-715-9871 (North America/Toll Free) or 646-307-1963 (U.S./Toll) and ask for the

IMUNON Year End 2025 Financial Results Call (Conference ID 4157104). A live webcast of the call will also be available here.

audio replay of the call will be available for 90 days and can be accessed at 800-770-2030 (U.S. and Canada/Toll Free), 609-800-9909

(U.S./Toll) or 647-362-9199 (Canada/Toll) using replay access code 4157104#.

About

IMUNON

is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural

mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach

from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®,

is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological

approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit

a strong immunological response.

The

Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer

that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical

trial (OVATION 3). The first patient was dosed in the Company’s Phase 3 pivotal study in the third quarter of 2025. IMNN-001 works

by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon

gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier

of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.

Forward-Looking

Statements

IMUNON

wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions

of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not

limited to, statements regarding the expected reduction of operating expenses related to the strategic reorganization, the timing of

enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs,

the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates,

and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements.

We generally identify forward-looking statements by using words such as “may,” “will,” “expect,”

“plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other

words or expressions referencing future events, conditions or circumstances), and include statements regarding our planned stock split.

Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, risks and uncertainties

related to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim

results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the

significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans;

possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s

filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or

supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Contacts:

Media

Investors

Life

ICR

Healthcare

Jenna

Urban

Peter

Vozzo

212-253-8881

443-213-0505

jurban@cglife.com

peter.vozzo@icrhealthcare.com

(Tables

to Follow)

IMUNON,

Inc.

Condensed

Consolidated Statements of Operations

(in

thousands except per share amounts)

Year Ended December 31,

2025

2024

Operating expenses:

Research and development

$ 7,781

$ 11,639

General and administrative

6,870

7,493

Total operating expenses

14,651

19,132

Loss from operations

(14,651 )

(19,132 )

Other income:

Investment income, net

156

512

Total other income, net

156

512

Net

loss

$ (14,495 )

$ (18,620 )

Net loss per common share

Basic and diluted

$ (6.83 )

$ (16.94 )

Weighted average shares outstanding

Basic and diluted

2,123

1,099

IMUNON,

Inc.

Selected

Balance Sheet Information

(in

thousands)

December 31, 2025

December

31, 2024

ASSETS

Current assets

Cash and cash equivalents

$ 8,781

$ 5,873

Advances, deposits on clinical programs and other current assets

1,943

2,136

Total current assets

10,724

8,009

Property and equipment

530

541

Other assets

Operating lease right-of-use assets, deposits, and other assets

1,034

1,167

Total other assets

1,034

1,167

Total assets

$ 12,288

$ 9,717

LIABILITIES

AND STOCKHOLDERS’ EQUITY

Current liabilities

Accounts payable and accrued liabilities

$ 4,217

$ 4,334

Operating lease liability – current portion

406

452

Total current liabilities

4,624

4,786

Operating lease liability – noncurrent portion

602

687

Total liabilities

5,226

5,473

Stockholders’ equity

Common stock

Additional paid-in capital

428,411

411,122

Accumulated deficit

(421,298 )

(406,803 )

7,147

4,329

Less: Treasury stock

(85 )

Total stockholders’ equity

7,062

4,244

Total liabilities and stockholders’ equity

$ 12,288

$ 9,717

# #

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (3118 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Mar. 31, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Mar. 31, 2026

Entity File Number

001-15911

Entity Registrant Name

Imunon,

Inc.

Entity Central Index Key

0000749647

Entity Tax Identification Number

52-1256615

Entity Incorporation, State or Country Code

Entity Address, Address Line One

997

Lenox Drive

Entity Address, Address Line Two

Suite 100

Entity Address, City or Town

Lawrenceville

Entity Address, State or Province

Entity Address, Postal Zip Code

08648-2311

City Area Code

(609)

Local Phone Number

896-9100

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

stock, par value $0.01 per share

Trading Symbol

IMNN

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration